Welcome to our dedicated page for Adagio Medical news (Ticker: ADGM), a resource for investors and traders seeking the latest updates and insights on Adagio Medical stock.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is a medical device company focused on catheter ablation technologies for cardiac arrhythmias, and its news flow centers on the development, clinical evaluation, and commercialization of its Ultra-Low Temperature Cryoablation (ULTC) platform. Company press releases highlight progress with the vCLAS Cryoablation System for ventricular tachycardia, key clinical milestones, financing events, and leadership updates.
Investors and clinicians following ADGM news will see regular updates on the FULCRUM-VT U.S. pivotal IDE study, which Adagio describes as a prospective, multi-center, open-label, single-arm trial designed to evaluate the safety and effectiveness of ULTC for recurring monomorphic ventricular tachycardia. News items include completion of enrollment, preliminary acute safety and effectiveness results presented at a major ventricular arrhythmia symposium, and plans to use study outcomes to support a future PMA application for vCLAS.
Adagio’s news releases also cover capital markets activity, such as the announcement and closing of a private placement intended to fund FDA submission activities, next-generation ULTC catheter development, and expansion of manufacturing and commercial readiness. Additional coverage includes governance and leadership changes, including the appointment of a Chief Business Officer who also serves as Chief Financial Officer, the addition of an industry veteran to the Board of Directors, and the hiring of senior executives in global sales and manufacturing and operations.
For those tracking ADGM, the news stream provides insight into clinical data disclosures, regulatory strategy, financing transactions, conference presentations, and board and management developments that the company identifies as important to its ULTC-based ventricular tachycardia program.
Adagio Medical (Nasdaq: ADGM) will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at 2:30 PM ET in Boston. A live webcast and replay will be available via the event platform and on the company investor website.
Investors can watch the presentation live or access the replay at the company's investor relations site.
Adagio Medical (Nasdaq: ADGM) published U.S. Early Feasibility Study results showing favorable safety and performance for ultralow temperature cardiac ablation (ULTC) in scar-related ventricular tachycardia.
In 20 patients across four U.S. centers, no device- or procedure-related major adverse events were seen at 7 and 30 days; 92.9% non-inducibility among 14 tested; 72% reduced or stopped antiarrhythmic drugs; 83.3% free from ICD shock at mean 24-week follow-up.
Adagio Medical (Nasdaq: ADGM) said management will present at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.
The participation highlights investor outreach and provides a forum to discuss product development and corporate strategy.
Adagio Medical (Nasdaq: ADGM) announced two senior hires to accelerate commercial readiness for its Ultra-Low Temperature Cardiac Ablation (ULTC) platform: Marie-Claude Jacques as Senior Vice President, Global Sales, and Antwan Gipson as Senior Vice President, Manufacturing & Operations, effective December 22, 2025.
Key points: Ms. Jacques brings 15+ years in electrophysiology and interventional cardiology, led a 100-person sales organization at Baylis and helped scale its EP portfolio to over $170 million in annual revenue. Mr. Gipson brings 20+ years in manufacturing and operations, citing prior scale-ups of production 10–100x and cost-of-goods reductions up to 75%. Management said these hires support planned commercialization in 2026.
Adagio Medical (Nasdaq: ADGM) announced on December 11, 2025 that Sean Salmon has been appointed to its Board of Directors and will join the company’s Audit Committee and Compensation Committee.
Mr. Salmon, 60, recently retired after a 20+ year tenure at Medtronic where he held senior global leadership roles across cardiovascular and diabetes businesses, including Executive Vice President and President of the Cardiovascular Portfolio. His background includes leadership in electrophysiology (EP) therapies, CE‑Mark and FDA approvals for the Pulse Select and Sphere 9 pulsed field ablation catheters, and strategic transactions such as the acquisition of Affera and the asset acquisition of Acutus’ transeptal crossing technology.
The appointment is positioned to support Adagio’s commercial planning, pipeline innovation, and operating oversight as the company advances its proprietary ultralow temperature ablation technology.
Adagio Medical (NASDAQ: ADGM) reported third quarter 2025 results and operational milestones on November 12, 2025. Key developments include a private placement announced October 20, 2025 providing up to $50 million in gross proceeds with ~$19 million upfront to fund FDA submission and next-generation catheter work. The company completed enrollment of the 209-patient FULCRUM-VT pivotal IDE trial for the vCLAS System and reported preliminary trial results showing 97% acute effectiveness and a favorable safety profile for its ultralow temperature technology. Q3 financials: cost of revenue $31,000; R&D $2.8 million; SG&A $2.9 million; net loss $10.1 million versus $4.6 million year-ago; cash and cash equivalents $4.7 million as of September 30, 2025.
Adagio Medical (Nasdaq: ADGM) said management will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 10:30 a.m. ET at the Lotte Palace in New York.
A live and recorded webcast will be available at the event webcast page: https://event.webcasts.com/starthere.jsp?ei=1742138&tp_key=f2a06e9abc.
Adagio Medical (Nasdaq: ADGM) announced on October 20, 2025 the closing of a private placement that generated $19 million upfront in net proceeds. The company said it will use the funds to support submission activities for the FULCRUM-VT pivotal study and a PMA filing for the vCLAS ULTC System, advance clinical experience and FDA submission work for a next-generation ULTC catheter, build awareness of ULTC for ventricular tachycardia (VT), expand manufacturing and commercial readiness, and strengthen corporate operations. Adagio noted it has treated over 350 patients across regulatory studies, commercial use, and compassionate cases and said the financing is expected to de-risk execution and extend its cash runway into key inflection points.
Adagio Medical (Nasdaq: ADGM) announced a private placement expected to provide approximately $19 million in upfront proceeds and up to $31 million of additional proceeds if warrants are exercised, for a combined potential of ~$50 million.
The company will issue an aggregate of 9,792,506 shares (or pre-funded warrants) and three warrant tranches of 6,012,943 warrants each, at a combined purchase price of $1.9403 per share and an accompanying warrant exercise price of $1.71. Warrants are exercisable immediately and expire on the earlier of five years or specified clinical/FDA milestone windows. Piper Sandler is sole placement agent; Lake Street is financial advisor. Proceeds are for working capital and clinical/product development. Closing expected the week of October 13, 2025, subject to customary conditions.
Adagio Medical (Nasdaq: ADGM) reported preliminary acute (within 7 days) results from the FULCRUM-VT pivotal study presented October 10, 2025. The multi‑center trial enrolled 207 patients at 19 US and Canadian sites with ischemic and nonischemic cardiomyopathy (mean LVEF 35%±10%).
Key acute outcomes: mean procedure duration 206±68 minutes, 97.4% acute clinical success (non‑inducibility) and 96.7% elimination of clinically relevant VTs. Safety: 2.5% major adverse event rate, including four peri‑procedural deaths (1.9%) and one death (0.5%) adjudicated as definitely device‑related. Six‑month primary efficacy results are planned for Heart Rhythm 2026.